To boldly and consistently commercialize first in class therapeutics through streamlining the drug development process and aligning the interests of development partners, investors, employees and patients.
KPI is focused on accelerating translational stage and other clinical drug programs to meet unmet patient needs. KPI’s partners and investors will supply funding and development expertise in a collaborative model focused on making the early clinical drug validation process more efficient and successful. KPI’s unique business model is designed not only to speed drug development but also to improve investor returns versus traditional industry models.
To accelerate novel therapeutics in areas of unmet patient need by improving the business and process of drug development and by leveraging an alliance of drug development partners under a common purpose.